KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Intangibles (2016 - 2025)

Jazz Pharmaceuticals has reported Intangibles over the past 16 years, most recently at $4.4 billion for Q4 2025.

  • Quarterly results put Intangibles at $4.4 billion for Q4 2025, down 6.86% from a year ago — trailing twelve months through Dec 2025 was $4.4 billion (down 6.86% YoY), and the annual figure for FY2025 was $4.4 billion, down 6.86%.
  • Intangibles for Q4 2025 was $4.4 billion at Jazz Pharmaceuticals, down from $4.6 billion in the prior quarter.
  • Over the last five years, Intangibles for JAZZ hit a ceiling of $7.6 billion in Q2 2021 and a floor of $1.0 million in Q3 2021.
  • Median Intangibles over the past 5 years was $5.2 billion (2024), compared with a mean of $4.9 billion.
  • Biggest five-year swings in Intangibles: crashed 99.96% in 2021 and later skyrocketed 556939.4% in 2022.
  • Jazz Pharmaceuticals' Intangibles stood at $7.2 billion in 2021, then dropped by 18.99% to $5.8 billion in 2022, then crashed by 87.01% to $752.5 million in 2023, then soared by 531.99% to $4.8 billion in 2024, then fell by 6.86% to $4.4 billion in 2025.
  • The last three reported values for Intangibles were $4.4 billion (Q4 2025), $4.6 billion (Q3 2025), and $4.8 billion (Q2 2025) per Business Quant data.